bipolar
Lundbeck appoints Tarek Samad as EVP, Head of Research & Development
Samad previously held senior research leadership positions at Immunitas Therapeutics, Sanofi and Pfizer
Lundbeck completes patient randomisation for phase 3 trial for multiple system atrophy treatment
The rare neurodegenerative disorder has no cure and no approved treatments
Lundbeck drops Parkinson’s drug acquired in €905m deal
Disappointment after drug failed in a mid-stage clinical trial
Lundbeck gets US approval for migraine drug at heart of Alder takeover
US regulator clears CGRP inhibitor under Vyepti trade name
Merck strengthens KRAS stake with Taiho and Astex partnership
Partner companies could gain $2.5bn in milestone payments
Otsuka presses on with Alzheimer’s agitation drug
Surprise announcement comes on the heels of phase 3 trial fail
Avanir’s week goes from bad to worse with Alzheimer’s stumble
Suffers a blow as second phase 3 trial misses the mark
Verily unveils next-gen trials alliance with Novartis, Pfizer
New data methods and tech will be used to streamline trials
Otsuka’s Alzheimer’s agitation drug hits the mark
Drug addresses one of the most challenging symptoms in dementia care